St. Luke’s Provides Treatment for COVID ‘Long Haulers’

April 16, 2021

St. Luke’s has introduced its new COVID Recovery Clinic, a program dedicated to the treatment of post-COVID-19 patients with lingering symptoms.

St. Luke’s recognizes the prevalence of “long COVID” symptoms and the need to care for patients afflicted by these symptoms appropriately.  Incorporating the expertise of a half dozen different kinds of medical specialists, the program promises a coordinated, multidisciplinary approach to Post-Acute Sequelae of COVID, known as PASC.  Participants will benefit from specialized evaluation and a personalized treatment plan.

“Many people recovering from COVID continue to have long-lasting symptoms that impact their day-to-day lives. St. Luke’s is committed to helping these patients get access to the most appropriate care so they can find relief,” said St. Luke’s Senior Regional Medical Director Dennis McGorry, MD, who is spearheading the program.

Nationally, PASC of varying severity is being reported in up to 30% of adults and children following COVID infection.

Most typical COVID cases resolve in four weeks, explained Jeffrey Jahre, MD, St. Luke’s Vice President of Medical & Academic Affairs and Section Chief Emeritus of Infectious Diseases.  But for some, the symptoms aren’t going away. “Patients are going to their doctor, asking, ‘What’s wrong with me?’ In many cases, people are not getting the appropriate care.”

The most common after-effects these patients, or “long haulers,” experience include extreme fatigue, memory impairment, known as “brain fog,” anxiety and depression, breathing difficulty and heart muscle irregularities or irregular heartbeats.

Patients with persistent symptoms beyond four weeks are advised to go to their St. Luke’s primary care physician, who will be able to evaluate them and may refer them to the COVID Recovery Clinic for further treatment by appropriate medical specialists.

Depending on a patient’s specific symptoms and their severity, treatment can include cognitive and memory retraining, physical and occupational therapy, medication and group therapy for behavioral health issues as well as other interventions to address neurologic, pulmonary and cardiac problems.

St. Luke’s has taken steps to help providers manage PASC, such as building a “smart set” algorithm into the electronic medical record system. The smart set guides physicians on ordering tests and imaging scans based on patients’ symptoms.

While some COVID after-effects may be mild, McGorry said, “The key is not missing something serious like a pulmonary embolism or cardiomyopathy (heart muscle issue) in these patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Tabrecta is the first FDA-approved therapy to treat non small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
The Cor® TRICUSPID ECM® valve has been successfully implanted in the 11th patient enrolled in the expansion by Dr. Marc Gerdisch, Chief of Cardiothoracic Surgery at Franciscan Health Heart Center in Indianapolis, Indiana & principal investigator for the adult component of the study.
Thirona notes LungQ 3.0.0 builds on 10 years of clinical trials and 200+ publications to deliver advanced segmentation of pulmonary segments and subsegments.
The Zeta Surgical Cranial Navigation System is a mixed-reality navigation system for neurosurgery, providing surgeons with "GPS-like" guidance with millimetric accuracy in real-time. Zeta's computer vision engine ensures maintained accuracy by automatically registering multiple times a second, accounting for patient movement, and allowing for awake and non-immobilized use in both operative and extra-operative settings.
The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.

By using this website you agree to accept Medical Device News Magazine Privacy Policy